Member Info for Bermudashorts

CrustyPete,

Regarding your comments on cohort 2 - I think this is simply a reflection of the treatment landscape for advanced melanoma rather than any refelction on recruitment to the trial itself. Where possible, consultants will prescribe the doublet therapy as it's has much higher efficacy than the single anti PD-1 checkpoint inhibitor. However, whilst the doublet therapy brings improved efficacy, it also brings added toxicity and not all patients are able to tolerate that toxicity - those patients will be prescribed the single PD-1 CPI. So cohort 2 is recruiting from a much smaller patient pool of only those patients who can't tolerate the doublet therapy and recruitment is inevitably going to be very slow. It will have no impact going forward on the speed of development of SCIB1/iSCIB1.

CW,

Both Lindy Durrant and Jean-Michel Cosséry took part in the placing last Nov/Dec.

https://www.lse.co.uk/rns/SCLP/results-of-placing-32ir0l6gq5ehvuo.html

https://www.lse.co.uk/rns/SCLP/pdmr-notification-vhaxe9breyfqwew.html

Miavoce

I'm sorry you have suffered so. Based on your response after this post I won't discuss any further.

There has been study after study looking for links between childhood vaccines and autism involving hundreds of thousands of children monitored over many years and searching as hard as possible for a link. They have found none.

Meanwhile vaccination rates for measles continue to decline - one of the most contagious diseases known to man with a death rate of 1 to 2 per 1000 cases. My biggest concern re. Kennedy has nothing to do with Scancell but is the impact on childhood vaccinations. Andrew Wakefield and those who have profiteered on the back of his completely discredited research have much to answer for.

Wish you all the best miavoce and hope your symptoms resolve and you are able to return to normal functioning.

Dracula,

Which drugs are you referring to?

Burble - post rec.

WTP

Well that answers my 11.07 from yesterday - thanks for that.

Konar,

Possibly although I'm not sure many were even aware that it hadn't been!

Balerno,

Biotheus's main assett and the reason for BioNTech's acquisition is their PD-L1/VEGF bispecific antibody, BNT327 but worth noting that BioNTech already owned the rights to this for all territories except China via a licensing deal completed a year ago and this would have been reflected in the valuation. So not quite as straightforward as it seems.

Quite a buzz around these PD-L1/VEGF bispecifics, wonder whether Scancell are carrying out any preclinical testing of modi-1/SCIBs in combination?

BioNTech to Acquire Biotheus to Boost Oncology Strategy.........

https://www.globenewswire.com/en/news-release/2024/11/13/2980068/0/en/BioNTech-to-Acquire-Biotheus-to-Boost-Oncology-Strategy.html

Thanks Ivy.

Also would like to know about JPM coming up in January.

Anyone know whether Scancell are attending Jefferies Healthcare Conference which begins next week? Would hope they'd be presenting but afaik Jefferies never publish details of attendees or presenting companies. Also starting next week to coincide with Jefferies is London Life Sciences Week, again I wonder whether Scancell will be playing any part? Timing fits in nicely with arrival of new CEO.

I wish Scancell would add and keep updated an events page on their website.

https://lifesciencesweek.london/

Almas/Ivy/ciaskin - thanks for taking the time to listen in and to Almas for the feedback.

Ciaskin - I guess as principal investigator for the ongoing Modi trial he has to be careful what is said but his comments do suggest that Scancell are no longer recruiting to the monotherapy arms of the trial.

Ruck - didn't Scancell recently say that the price for SCIB1 could be in the region of £100k? Slightly at odds with CO's estimate for off the shelf vaccines.

Missed this back in June, but congratulations to Jeremy Green:-

Outstanding contributions by British nationals abroad recognised on King’s Birthday 2024 Overseas and International honours list.

Jeremy Green

Founder and Managing Partner of the Redmile Group, receives a CBE [Commander of the Order of the British Empire] for services to Business, Philanthropy and Support to the King’s Trust.

Jeremy Green is recognised for his outstanding contribution in 2 different areas: his impact in the UK life sciences sector; and his sustained service in support of the King’s Trust. Mr Green founded Redmile Group in 2007 which has grown into one of the largest life science investment firms in the world. While Mr Green’s outlook is global, Redmile is a significant investor in the UK sector, including leading financing rounds for some of the UK’s most impactful life sciences companies. He has also served on multiple taskforces focused on fostering growth of the life science sector and ensuring the UK becomes a hub for investment. Mr Green has also served The King’s Trust for over 2 decades and remains heavily engaged as a Trustee of King’s Trust Group and the Chair of the King’s Trust USA, helping to lead its programme and fundraising work.

On learning of his award, Jeremy Green said:

It is a privilege to work with both the scientists and entrepreneurs doing vital work in the life science sector and our team at the King’s Trust who ensure young people from around the world have a chance to succeed. An honour such as this is really recognition of their work, and I am grateful to be part of both communities.

https://www.gov.uk/government/news/outstanding-contributions-by-british-nationals-abroad-recognised-on-kings-birthday-2024-overseas-and-international-honours-list

Evaxion have a few struggles of their own at the moment, cash is low and they're failing to comply with Nasdaq minimum listing requirements so are currently under threat of being delisted. Having said that their lead melanoma vax. EVX-01 does look like it's producing some very promising results in similar nos. of patients to Scancell so far so I hope they are able to attract the funding to develop their pipeline.

The point is though that this discussion really highlights the difference between personalised and off the shelf vaccines.

Evaxion have to rely on AI due to the nature of personalised vaccines. The tumour is analysed and they then use AI to select the best antigens to target with their vax but Scancell don't need to go through that process as they're targeting the same antigens every time for every patient. The market and the field is vast and certainly big enough for both to find a place.

I know someone mentioned this the other day but can't remember who and exactly what was said, but think there is more detail in this announcement from PharmaJet today:-

'Scancell: The Phase 2 trial with patients that have advanced unresectable melanoma who have received the SCIB1 or ISCIB1+ DNA vaccine with CPI, either with nivolumab and ipilimumab or pembrolizumab is ongoing. Latest data shows SCIB1 administered with Stratis has induced T cell responses in 87% of patients who have been given double CPI and showed a significant increase from baseline T cell counts with full cohort data still to be analyzed.3 According to Lindy Durrant, Scancell CEO, “To date, Stratis is the only technology which has shown effective uptake of the DNA vaccine through intramuscular delivery allowing native cellular machinery to express the target antigen and induce a potent anti-tumor response.”

https://pharmajet.com/pharmajet-poster-presentation-at-cancer-immunotherapy-conference-highlights-how-needle-free-technology-is-enhancing-oncology-solutions/

Ruck - yes it is although lately they seem to have hinted that they may be open to licensing. This isn't a new paper - it was published back in August and has been discussed at least a couple of times on here.

Mark -

I know and I will filter, but this 25 week scan issue is a really important point which has now been made.

I know LD said it - you provided the link! This is what she said:-

'We had a bit of a slow down with the SCIB1 because iSCIB1+ was pending so people wanted to go into the new vaccine'

Could be any reason for that - could be down to the screening process as HLA status would only be known after patient enrolled and screened in any case. Or it could be investigators wanting to push patients into iSCIB1+ . You've chosen to believe and announce publicly that LD is a liar without even checking with her first why iSCIB1+ pending affected recruitment for SCIB1. You've also stated that if any of the 11 responders announced to date show progression at the 25 week scan then they will not count as responders and not count when calculating ORR for the study - not true.

Re. the opening of iSCIB1+ cohort slowing down recruitment for SCIB1 - I did listen to the link and have no idea why that would happen. CW is right in that respect though, rather than publicly calling LD a liar and accusing her of misleading shareholders, why don't you ask her what she meant?

Not nonsense at all and suggest rather than wasting your time arguing here you check with her yourself.